Boehringer Ingelheim has made a significant discovery with the identification of spesolimab, an investigational medication that shows promise in preventing flares in adults suffering from generalized pustular psoriasis (GPP).
The drug has received approval from the U.S. Food and Drug Administration.
Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening chronic skin condition characterized by the emergence of painful, sterile pustules throughout the body, causing significant disruptions to a person's well-being. These flares can result in hospitalization due to severe complications like heart failure, renal failure, sepsis, and even mortality.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) has introduced SPEVIGO (spesolimab-sbzo) injection, an intravenous medication marketed as Spesolimab. It is specifically indicated for treating flares of GPP in adult patients.
Spesolimab is currently undergoing research for potential utilization in various scenarios involving generalized pustular psoriasis (GPP).
However, it should be noted that the safety and effectiveness of spesolimab in these particular situations have yet to be established.
It is important to emphasize that SPEVIGO (spesolimab-sbzo) injection, intended for intravenous administration, has not received approval for any additional applications in adults or pediatric patients.